PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34697991-3 2021 Fluvoxamine can bind to S1R and reduce the serotonin uptake of neurons and platelets. Fluvoxamine 0-11 sigma non-opioid intracellular receptor 1 Rattus norvegicus 24-27 34630662-6 2021 MI rats were administered different treatments, including normal saline, YQHX and fluvoxamine, an agonist of the Sigma-1 receptor. Fluvoxamine 82-93 sigma non-opioid intracellular receptor 1 Rattus norvegicus 113-129 31493481-10 2019 SIGNIFICANCE: Our findings indicated that S1R inhibition contributed to atrial electrical remodeling, cardiac autonomic remodeling and atrial fibrosis, which could be attenuated by fluvoxamine, thus providing new insights into the relationship between the S1R and AF. Fluvoxamine 181-192 sigma non-opioid intracellular receptor 1 Rattus norvegicus 42-45 35473584-2 2022 Monocrotaline (60 mg/kg) was administered to induce pulmonary arterial hypertension, and fluvoxamine was given for 21 consecutive days to activate S1R after one week of monocrotaline administration. Fluvoxamine 89-100 sigma non-opioid intracellular receptor 1 Rattus norvegicus 147-150 33140216-10 2021 Thus, we investigated the effect of fluvoxamine, a Sigma-1 receptor agonist, on Ito and ICa-L. Fluvoxamine enhanced Ito and altered its current kinetics, as shown by acceleration of activation and recovery from inactivation. Fluvoxamine 95-106 sigma non-opioid intracellular receptor 1 Rattus norvegicus 51-67 33488945-8 2021 Fluvoxamine stimulation of Sig1R restored autophagic flux in cardiac fibroblasts, indicating that Sig1R appears to play a protective role in the activation of cardiac fibroblasts by inhibiting the IRE1 pathway and restoring autophagic flux. Fluvoxamine 0-11 sigma non-opioid intracellular receptor 1 Rattus norvegicus 27-32 33488945-8 2021 Fluvoxamine stimulation of Sig1R restored autophagic flux in cardiac fibroblasts, indicating that Sig1R appears to play a protective role in the activation of cardiac fibroblasts by inhibiting the IRE1 pathway and restoring autophagic flux. Fluvoxamine 0-11 sigma non-opioid intracellular receptor 1 Rattus norvegicus 98-103 32629001-3 2020 The S1R agonist fluvoxamine was injected intraperitoneally from the second week to the last week for 21 days in total, and the effects were evaluated by patch clamp, western blot analysis, and Masson staining. Fluvoxamine 16-27 sigma non-opioid intracellular receptor 1 Rattus norvegicus 4-7 31493481-10 2019 SIGNIFICANCE: Our findings indicated that S1R inhibition contributed to atrial electrical remodeling, cardiac autonomic remodeling and atrial fibrosis, which could be attenuated by fluvoxamine, thus providing new insights into the relationship between the S1R and AF. Fluvoxamine 181-192 sigma non-opioid intracellular receptor 1 Rattus norvegicus 256-259 24373833-0 2014 Fluvoxamine rescues mitochondrial Ca2+ transport and ATP production through sigma(1)-receptor in hypertrophic cardiomyocytes. Fluvoxamine 0-11 sigma non-opioid intracellular receptor 1 Rattus norvegicus 76-93 30902656-2 2019 Fluvoxamine enhances nerve growth factor (NGF)-induced neurite outgrowth in PC12 cells via a sigma-1 receptor-mediated mechanism, which suggests that neurogenesis may be involved in the antidepressant action of fluvoxamine. Fluvoxamine 0-11 sigma non-opioid intracellular receptor 1 Rattus norvegicus 93-109 30902656-2 2019 Fluvoxamine enhances nerve growth factor (NGF)-induced neurite outgrowth in PC12 cells via a sigma-1 receptor-mediated mechanism, which suggests that neurogenesis may be involved in the antidepressant action of fluvoxamine. Fluvoxamine 211-222 sigma non-opioid intracellular receptor 1 Rattus norvegicus 93-109 28315270-5 2017 Several clinical studies showed that sigma-1 receptor agonists such as fluvoxamine and ifenprodil could have beneficial effects in patients with neuropsychiatric disorders. Fluvoxamine 71-82 sigma non-opioid intracellular receptor 1 Rattus norvegicus 37-53 27056295-4 2017 In rats, pretreatment with either dehydroepiandrosterone or fluvoxamine, a high-affinity sigma1-receptor agonist, improved survival, renal function and structure, and the inflammatory response after sublethal renal ischemia-reperfusion injury. Fluvoxamine 60-71 sigma non-opioid intracellular receptor 1 Rattus norvegicus 89-104 27056295-5 2017 In human proximal tubular epithelial cells, stimulation by fluvoxamine or oxidative stress caused the sigma1-receptor to translocate from the endoplasmic reticulum to the cytosol and nucleus. Fluvoxamine 59-70 sigma non-opioid intracellular receptor 1 Rattus norvegicus 102-117 27056295-6 2017 Fluvoxamine stimulation in these cells also activated nitric oxide production that was blocked by sigma1-receptor knockdown or Akt inhibition. Fluvoxamine 0-11 sigma non-opioid intracellular receptor 1 Rattus norvegicus 98-113 27056295-7 2017 Similarly, in the postischemic rat kidney, sigma1-receptor activation by fluvoxamine triggered the Akt-nitric oxide synthase signaling pathway, resulting in time- and isoform-specific endothelial and neuronal nitric oxide synthase activation and nitric oxide production. Fluvoxamine 73-84 sigma non-opioid intracellular receptor 1 Rattus norvegicus 43-58 27056295-8 2017 Concurrently, intravital two-photon imaging revealed prompt peritubular vasodilation after fluvoxamine treatment, which was blocked by the sigma1-receptor antagonist or various nitric oxide synthase blockers. Fluvoxamine 91-102 sigma non-opioid intracellular receptor 1 Rattus norvegicus 139-154 26809458-3 2016 OBJECTIVES: We studied the dose-dependent efficacy of S1R agonist fluvoxamine (FLU) in the prevention of DM-induced depression and investigated the significance of the S1R-BDNF pathway. Fluvoxamine 66-77 sigma non-opioid intracellular receptor 1 Rattus norvegicus 54-57 26809458-3 2016 OBJECTIVES: We studied the dose-dependent efficacy of S1R agonist fluvoxamine (FLU) in the prevention of DM-induced depression and investigated the significance of the S1R-BDNF pathway. Fluvoxamine 79-82 sigma non-opioid intracellular receptor 1 Rattus norvegicus 54-57 24709917-2 2014 Fluvoxamine, one of the currently known antidepressants, is a sigma-1 receptor agonist; its effectiveness in treating acute cerebral ischemia has not been reported. Fluvoxamine 0-11 sigma non-opioid intracellular receptor 1 Rattus norvegicus 62-78 24709917-8 2014 Moreover, NE-100, a selective sigma-1 receptor antagonist, completely blocked the neuroprotective effect of fluvoxamine. Fluvoxamine 108-119 sigma non-opioid intracellular receptor 1 Rattus norvegicus 30-46 24709917-9 2014 The present findings suggest that the sigma-1 receptor agonist fluvoxamine reduces infarct volume and ameliorates neurological impairment even on postischemic treatment. Fluvoxamine 63-74 sigma non-opioid intracellular receptor 1 Rattus norvegicus 38-54 24373833-9 2014 These mechanisms likely underlie in part the anti-hypertrophic and cardioprotective action of the sigma1R agonists including fluvoxamine. Fluvoxamine 125-136 sigma non-opioid intracellular receptor 1 Rattus norvegicus 98-105 30543144-7 2019 Interestingly, the sigma-1 receptor antagonist NE-100 blocked the improvement effects of fluvoxamine on NGF-induced neurite outgrowth inhibition by DEX. Fluvoxamine 89-100 sigma non-opioid intracellular receptor 1 Rattus norvegicus 19-35 30543144-9 2019 These results indicate that the improvement effects of fluvoxamine on NGF-induced neurite outgrowth inhibition by DEX may be attributable to the phosphorylation of Akt and the sigma-1 receptor. Fluvoxamine 55-66 sigma non-opioid intracellular receptor 1 Rattus norvegicus 176-192 24508523-5 2014 The order of potency for drugs at the sigma-1 receptor chaperone was as follows: fluvoxamine>sertraline>fluoxetine>escitalopram>citalopram>paroxetine>duoxetine. Fluvoxamine 81-92 sigma non-opioid intracellular receptor 1 Rattus norvegicus 38-54 24508523-7 2014 Furthermore, fluvoxamine, fluoxetine, escitalopram, and mirtazapine significantly potentiated NGF-induced neurite outgrowth in cell assays, and the effects of all these drugs, excluding mirtazapine, were antagonized by NE-100, a selective antagonist of the sigma-1 receptor chaperone. Fluvoxamine 13-24 sigma non-opioid intracellular receptor 1 Rattus norvegicus 257-273 24508523-10 2014 These findings suggest that activation at the sigma-1 receptor chaperone may be involved in the action of some SSRIs, such as fluvoxamine, fluoxetine and escitalopram. Fluvoxamine 126-137 sigma non-opioid intracellular receptor 1 Rattus norvegicus 46-62 24373833-1 2014 AIMS: We previously reported that fluvoxamine, a selective serotonin reuptake inhibitor with high affinity for the sigma1-receptor (sigma1R), ameliorates cardiac hypertrophy and dysfunction via sigma1R stimulation. Fluvoxamine 34-45 sigma non-opioid intracellular receptor 1 Rattus norvegicus 115-130 24373833-1 2014 AIMS: We previously reported that fluvoxamine, a selective serotonin reuptake inhibitor with high affinity for the sigma1-receptor (sigma1R), ameliorates cardiac hypertrophy and dysfunction via sigma1R stimulation. Fluvoxamine 34-45 sigma non-opioid intracellular receptor 1 Rattus norvegicus 132-139 24373833-1 2014 AIMS: We previously reported that fluvoxamine, a selective serotonin reuptake inhibitor with high affinity for the sigma1-receptor (sigma1R), ameliorates cardiac hypertrophy and dysfunction via sigma1R stimulation. Fluvoxamine 34-45 sigma non-opioid intracellular receptor 1 Rattus norvegicus 194-201 24373833-5 2014 Interestingly, sigma1R stimulation with fluvoxamine rescued impaired mitochondrial Ca(2+) mobilization and ATP production, an effect abolished by treatment of cells with the sigma1R antagonist, NE-100. Fluvoxamine 40-51 sigma non-opioid intracellular receptor 1 Rattus norvegicus 15-22 24373833-5 2014 Interestingly, sigma1R stimulation with fluvoxamine rescued impaired mitochondrial Ca(2+) mobilization and ATP production, an effect abolished by treatment of cells with the sigma1R antagonist, NE-100. Fluvoxamine 40-51 sigma non-opioid intracellular receptor 1 Rattus norvegicus 174-181 24373833-8 2014 SIGNIFICANCE: These results suggest that sigma1R stimulation with fluvoxamine promotes SR-mitochondrial Ca(2+) transport and mitochondrial ATP production, whereas sigma1R stimulation suppresses intracellular Ca(2+) overload through IP3Rs and RyRs. Fluvoxamine 66-77 sigma non-opioid intracellular receptor 1 Rattus norvegicus 41-48 20722474-5 2010 The fluvoxamine administration significantly attenuated PO-induced myocardial hypertrophy with concomitant increase in the expression of Sig-1R in LV. Fluvoxamine 4-15 sigma non-opioid intracellular receptor 1 Rattus norvegicus 137-143 23428811-6 2013 Our findings suggest that SSRIs such as fluvoxamine protect against PO- and TAC-induced cardiac dysfunction by upregulating sigma-1 receptor expression and stimulating sigma-1 receptor-mediated Akt-eNOS signaling. Fluvoxamine 40-51 sigma non-opioid intracellular receptor 1 Rattus norvegicus 124-140 23428811-6 2013 Our findings suggest that SSRIs such as fluvoxamine protect against PO- and TAC-induced cardiac dysfunction by upregulating sigma-1 receptor expression and stimulating sigma-1 receptor-mediated Akt-eNOS signaling. Fluvoxamine 40-51 sigma non-opioid intracellular receptor 1 Rattus norvegicus 168-184 21044620-7 2011 Fluvoxamine"s vasculoprotective effect was nullified by co-administration of a sigma-1 receptor antagonist. Fluvoxamine 0-11 sigma non-opioid intracellular receptor 1 Rattus norvegicus 79-95 22288409-5 2012 Among SSRIs, fluvoxamine, a potent sigma-1 receptor agonist, has the highest affinity at sigma-1 receptors. Fluvoxamine 13-24 sigma non-opioid intracellular receptor 1 Rattus norvegicus 35-51 22288409-7 2012 Furthermore, phencyclidine (PCP)-induced cognitive impairment, associated with animal models of schizophrenia is significantly improved by sub-chronic administration of sigma-1 receptor agonists such as fluvoxamine, SA4503 (cutamesine) and donepezil. Fluvoxamine 203-214 sigma non-opioid intracellular receptor 1 Rattus norvegicus 169-185 22288409-9 2012 A positron emission tomography (PET) study using the specific sigma-1 receptor ligand [11C]SA4503 demonstrates that fluvoxamine and donepezil bind to sigma-1 receptors in the healthy human brain. Fluvoxamine 116-127 sigma non-opioid intracellular receptor 1 Rattus norvegicus 62-78 22288409-10 2012 In clinical studies, some sigma-1 receptor agonists, including fluvoxamine, donepezil and neurosteroids, improve cognitive impairment and clinical symptoms in neuropsychiatric diseases. Fluvoxamine 63-74 sigma non-opioid intracellular receptor 1 Rattus norvegicus 26-42 21044620-0 2011 Sigma-1 receptor stimulation with fluvoxamine activates Akt-eNOS signaling in the thoracic aorta of ovariectomized rats with abdominal aortic banding. Fluvoxamine 34-45 sigma non-opioid intracellular receptor 1 Rattus norvegicus 0-16 20722474-0 2010 Targeting sigma-1 receptor with fluvoxamine ameliorates pressure-overload-induced hypertrophy and dysfunctions. Fluvoxamine 32-43 sigma non-opioid intracellular receptor 1 Rattus norvegicus 10-26 20722474-1 2010 OBJECTIVE: We here investigated the effect of sigma-1 receptor (Sig-1R) stimulation with fluvoxamine on myocardial hypertrophy, cardiac functional recovery and defined mechanisms underlying its cardioprotective action. Fluvoxamine 89-100 sigma non-opioid intracellular receptor 1 Rattus norvegicus 46-62 20722474-1 2010 OBJECTIVE: We here investigated the effect of sigma-1 receptor (Sig-1R) stimulation with fluvoxamine on myocardial hypertrophy, cardiac functional recovery and defined mechanisms underlying its cardioprotective action. Fluvoxamine 89-100 sigma non-opioid intracellular receptor 1 Rattus norvegicus 64-70 20722474-10 2010 Fluvoxamine treatment protects PO-induced cardiac injury via upregulation of Sig-1R and stimulation of Sig-1R-mediated Akt-eNOS signaling in ovariectomized rats. Fluvoxamine 0-11 sigma non-opioid intracellular receptor 1 Rattus norvegicus 77-83 20722474-10 2010 Fluvoxamine treatment protects PO-induced cardiac injury via upregulation of Sig-1R and stimulation of Sig-1R-mediated Akt-eNOS signaling in ovariectomized rats. Fluvoxamine 0-11 sigma non-opioid intracellular receptor 1 Rattus norvegicus 103-109 20021354-5 2009 In a cell culture system, we demonstrated that fluvoxamine, but not sertraline or paroxetine, significantly potentiated nerve-growth factor (NGF)-induced neurite outgrowth in PC12 cells, and that the effect of fluvoxamine on NGF-induced neurite outgrowth was significantly antagonized by treatment with the selective sigma-1 receptor antagonist NE-100. Fluvoxamine 47-58 sigma non-opioid intracellular receptor 1 Rattus norvegicus 317-333 19995565-7 2010 Here, we examined whether fluvoxamine (FLV) activated Akt-1 and increased phosphorylation of Akt-1 via sigma-1 receptor in PC12 cells. Fluvoxamine 26-37 sigma non-opioid intracellular receptor 1 Rattus norvegicus 103-119 19995565-7 2010 Here, we examined whether fluvoxamine (FLV) activated Akt-1 and increased phosphorylation of Akt-1 via sigma-1 receptor in PC12 cells. Fluvoxamine 39-42 sigma non-opioid intracellular receptor 1 Rattus norvegicus 103-119 20021354-7 2009 Moreover, a recent study using the specific sigma-1 receptor ligand [(11)C] SA4503 and positron emission tomography (PET) have demonstrated that an oral administration of fluvoxamine, but not paroxetine, could bind to sigma-1 receptors in the healthy human brain, in a dose-dependent manner. Fluvoxamine 171-182 sigma non-opioid intracellular receptor 1 Rattus norvegicus 44-60 18596927-3 2008 The SSRI fluvoxamine, with sigma-1 receptor agonism, is shown to potentiate nerve-growth factor (NGF)-induced neurite outgrowth in PC 12 cells. Fluvoxamine 9-20 sigma non-opioid intracellular receptor 1 Rattus norvegicus 27-43 18596927-9 2008 The potentiation by fluvoxamine and the three sigma-1 receptor agonists was blocked by co-administration of the selective sigma-1 receptor antagonist NE-100, suggesting that sigma-1 receptors play a role in blocking the enhancement of NGF-induced neurite outgrowth. Fluvoxamine 20-31 sigma non-opioid intracellular receptor 1 Rattus norvegicus 122-138 18596927-12 2008 CONCLUSION: These findings suggest that stimulation of sigma-1 receptors and subsequent interaction with IP(3) receptors, PLC-gamma, PI3K, p38MAPK, JNK, and the Ras/Raf/MAPK signaling pathways are involved in the mechanisms of action of sigma-1 receptor agonists such as fluvoxamine and SA4503. Fluvoxamine 271-282 sigma non-opioid intracellular receptor 1 Rattus norvegicus 55-71